- SYNB1020 Oral Treatment Resulted in a Significant Dose-Dependent Effect on a Plasma Nitrogen Endpoint Demonstrating Mechanistic Activity - - Data Support Initiation of Two Phase 1b/2a Studies in 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic, Inc .,( Nasdaq:SYBX ) a
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2017-- Synlogic ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to SYNB1618,
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 10, 2017-- Synlogic ( Nasdaq: SYBX ) announced the addition of two experienced executives to key leadership roles: Andrew Gengos as Chief Operating Officer and Head of Corporate Development, and Adam Thomas as Chief Human Resources Officer.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Synlogic’s president and chief executive officer, will present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at 4:00 p.m.
Data support the lead clinical program in urea cycle disorders (UCD) and the further development of Synthetic Biotic™ candidates as potential treatments for phenylketonuria (PKU) and maple syrup urine disease (MSUD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2017-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., will present a company overview at BioCentury’s 24 th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017 , at 10:00
- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell , Ph.D., and Richard Shea CAMBRIDGE,
– Novel Synthetic Biotic™ medicine, SYNB1020, under development for the treatment of hyperammonemia due to urea cycle disorders – CAMBRIDGE, Mass–( BUSINESS WIRE )–Synlogic™ has been granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate,
– Discoveries support next phase of collaboration with AbbVie – Cambridge, Mass (Business Wire) – Synlogic™ has completed the first phase of its ongoing collaboration with AbbVie. During this first discovery phase of the collaboration Synlogic has identified Synthetic